One good place I always start in this search is to look at what insiders are purchasing. Zymeworks is pursuing using Zanidatamab to target a variety of HER2-expressing cancers in combination with other drugs and also as a monotherapy. Revenue should be up just over 40% for FY2022 when the company reports fourth quarter results early next month. The company gets approximately half of its revenue from crude oil and the rest from natural gas and natural gas liquids. This has triggered a company director to purchase just over $2.6 million worth of stock a week ago.

Source: New York Times January 20, 2023 15:22 UTC